Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: GlobeNewswire
KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights and updates on its pipeline. “We set a high bar for what we wanted to achieve in 2025 and exceeded expectat
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics (KYMR) had its "outperform" rating reaffirmed by Royal Bank Of Canada.MarketBeat
- Kymera Therapeutics (KYMR) had its price target lowered by BTIG Research from $138.00 to $134.00. They now have a "buy" rating on the stock.MarketBeat
- Kymera Therapeutics (KYMR) had its price target raised by Piper Sandler from $125.00 to $140.00. They now have an "overweight" rating on the stock.MarketBeat
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics to Participate in Upcoming March Investor ConferencesGlobeNewswire
KYMR
Earnings
- 2/26/26 - Miss
KYMR
Sec Filings
- 2/26/26 - Form 8-K
- 2/26/26 - Form 424B3
- 2/26/26 - Form 424B5
- KYMR's page on the SEC website